Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.50 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24347884 | 0.89 | HSP90AB1 (0.58) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL1219080 | 0.85 | OPRM1 (0.66) | HSP90AB1OPRM1HSP90AA1OPRK1OPRD1 | |
| SCHEMBL1220212 | 0.84 | HSP90AB1 (0.50) | HSP90AB1OPRM1HSP90AA1OPRK1OPRD1 | |
| SCHEMBL27977070 | 0.83 | HSP90AB1 (0.57) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3627633 | 0.83 | HSP90AB1 (0.56) | HSP90AB1OPRM1HSP90AA1OPRK1OPRD1 | |
| SCHEMBL20648826 | 0.83 | HSP90AB1 (0.64) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL1394304 | 0.82 | GRIA2 (0.39) | HSP90AB1 | |
| SCHEMBL5001569 | 0.81 | HSP90AB1 (0.52) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3633261 | 0.81 | HSP90AB1 (0.52) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL27196733 | 0.80 | HSP90AB1 (0.61) | HSP90AB1OPRM1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | claimed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | claimed |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2014-11-20 | — | — | US | claimed |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. | 2013-05-30 | — | — | US | claimed |
| EP-2380879-A1 | Tetrahydroindolone and tetrahydroindazolone derivatives | Serenex, Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| US-20110252835-A1 | HEAT PUMP (SERVER) COUPLED WASHER AND DRYER PAIR | WHIRLPOOL CORPORATION (US) | 2011-10-20 | — | — | US | claimed |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-07-28 | — | — | US | claimed |
| JP-4377942-B2 | — | — | 2009-12-02 | — | — | JP | claimed |
| JP-2008531599-A | — | — | 2008-08-14 | — | — | JP | claimed |
| CN-101180275-A | Tetrahydroindolone and tetrahydroindazolone derivatives | SERENEX INC (US) | 2008-05-14 | — | — | CN | claimed |
| EP-1856057-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | Serenex, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006091963-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-117820416-A | Hsp90PROTAC compound, preparation method thereof and application thereof in preparation of anti-cervical cancer drugs | 武汉大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20230391792-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-1856057-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | Serenex, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | ESANEX, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006091963-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391792-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMC2, PSMB11 | HSP90AB1 73/4885OPRM1 4301/4885HSP90AA1 85/4885 |
| US-20130137686-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | HSP90AB1 3419/4885OPRM1 2755/4885HSP90AA1 3912/4885 |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | HRH4, P2RX4, CDK4 | HSP90AB1 2805/4885OPRM1 2119/4885HSP90AA1 3248/4885 |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMC2, PSMA6 | HSP90AB1 114/4885OPRM1 4190/4885HSP90AA1 135/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSP90AB1 3419/4885OPRM1 2755/4885HSP90AA1 3912/4885 |
| US-20140343037-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | HSP90AB1 3419/4885OPRM1 2755/4885HSP90AA1 3912/4885 |
| US-20060211737-A1 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | HSF1, HSPA4, HSP90AB1 | HSP90AB1 3/4885OPRM1 3870/4885HSP90AA1 4/4885 |
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | HSP90AB1 3419/4885OPRM1 2755/4885HSP90AA1 3912/4885 |
| US-20110183977-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | HSP90AB1 3419/4885OPRM1 2755/4885HSP90AA1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.